Tofogliflozin
| Code | Size | Price |
|---|
| TAR-T13179-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Tofogliflozin is a highly specific inhibitor of sodium/glucose cotransporter 2 (SGLT2) (Kis: 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2. IC50s: 2.9/14.9/6.4 nM (human/rat/mouse SGLT2)).
CAS:
903565-83-3
Formula:
C22H26O6
Molecular Weight:
386.444
Purity:
0.98
SMILES:
CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@H](O)[C@H](O)[C@H]4O)c3c2)cc1
References
1. Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170(3):519-31.
2. Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobioti
3. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701.
4. Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23.